Marshall Wace
CHRS icon

Marshall Wace’s Coherus Oncology CHRS Stock Holding History

Marshall Wace’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Buy
270,087
+184,623
+216% +$328K ﹤0.01% 2488
2025
Q4 		$121K Buy
+85,464
New +$125K ﹤0.01% 2687
2024
Q3 		– Sell
-420,326
Closed -$727K – 2550
2024
Q2 		$727K Buy
420,326
+268,763
+177% +$541K ﹤0.01% 1814
2024
Q1 		$362K Buy
151,563
+34,383
+29% +$84.6K ﹤0.01% 2048
2023
Q4 		$390K Sell
117,180
-2,195,026
-95% -$5.88M ﹤0.01% 1801
2023
Q3 		$8.65M Buy
2,312,206
+28,815
+1% +$133K 0.02% 689
2023
Q2 		$9.75M Buy
2,283,391
+1,710,463
+299% +$10.1M 0.02% 738
2023
Q1 		$3.92M Buy
+572,928
New +$4.45M 0.01% 1117
2022
Q4 		– Sell
-30,534
Closed -$294K – 2977
2022
Q3 		$294K Buy
+30,534
New +$309K ﹤0.01% 2960
2021
Q2 		– Sell
-34,610
Closed -$505K – 2696
2021
Q1 		$505K Buy
+34,610
New +$588K ﹤0.01% 1934
2019
Q3 		– Sell
-9,339
Closed -$207K – 1689
2019
Q2 		$207K Buy
+9,339
New +$162K ﹤0.01% 1243
2018
Q4 		– Sell
-237,182
Closed -$3.91M – 1609
2018
Q3 		$3.91M Buy
237,182
+210,824
+800% +$3.74M 0.03% 517
2018
Q2 		$369K Buy
+26,358
New +$377K 0.01% 610
2017
Q1 		– Sell
-36,303
Closed -$1.02M – 373
2016
Q4 		$1.02M Buy
+36,303
New +$1.02M 0.01% 751

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Marshall Wace's CHRS Position: Q1 2026 in Review

Marshall Wace increased its Coherus Oncology (CHRS) stake by 216% in Q1 2026, buying an estimated $328K and bringing the position to 270,087 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

Marshall Wace first reported a position in CHRS in Q4 2016 and has held it in 14 quarters since. The position peaked at $9.75M in Q2 2023. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Marshall Wace held 270,087 shares of Coherus Oncology worth $456K as of Q1 2026.
  • Marshall Wace bought 184,623 Coherus Oncology shares in Q1 2026, an estimated $328K.
  • Coherus Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2488 holding.
  • Marshall Wace first reported a position in Coherus Oncology in Q4 2016 and has held it in 14 quarters since.
  • Marshall Wace's Coherus Oncology position peaked at $9.75M in Q2 2023.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.